Krista Davis Sells 1,730 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,730 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $77.99, for a total value of $134,922.70. Following the completion of the sale, the senior vice president directly owned 49,263 shares of the company’s stock, valued at approximately $3,842,021.37. The trade was a 3.39% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Krista Davis also recently made the following trade(s):

• On Thursday, February 19th, Krista Davis sold 2,084 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $77.53, for a total value of $161,572.52.
• On Thursday, December 18th, Krista Davis sold 1,622 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.40, for a total transaction of $133,652.80.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock traded down $2.67 during midday trading on Monday, hitting $75.10. The company had a trading volume of 336,650 shares, compared to its average volume of 466,618. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. ANI Pharmaceuticals, Inc. has a 1-year low of $54.10 and a 1-year high of $99.50. The business’s 50 day simple moving average is $80.82 and its two-hundred day simple moving average is $86.59. The stock has a market cap of $1.69 billion, a PE ratio of 46.07 and a beta of 0.50.

Analysts Set New Price Targets

Several research firms have commented on ANIP. Barclays started coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target for the company. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $103.43.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors have recently bought and sold shares of ANIP. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals during the first quarter worth $28,000. Hantz Financial Services Inc. grew its holdings in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 237 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of ANI Pharmaceuticals by 4,636.4% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after purchasing an additional 510 shares in the last quarter. Newbridge Financial Services Group Inc. lifted its holdings in ANI Pharmaceuticals by 200.0% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 400 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at about $48,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.